Webinars

MDOutlook is pleased to release the third report on the clinical impact of new data presented at ASCO and EHA 2015. This report includes analyses from 2 studies in hematologic malignancies involving more than 150 oncologists and hematologists with identified focus on Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM).

MDOutlook celebrates its 8th consecutive year of syndicated research gauging the clinical impact of new data presented at ASCO 2015. Building on over 30 analyses since 2008, MDOutlook today releases the first analysis in a new series covering solid and liquid tumors. This OncoPoll™ focuses on the continued evolution of

Built upon years of experience and appreciating the multi-factorial complexity of identifying and engaging ThoughtLeaders, MDOutlook has developed robust algorithms to capture all attributes of a ThoughtLeader's impact on the market. MDOutlook delivers 360° profiles of identified ThoughtLeaders, uniquely meshing public and proprietary data. Through our exclusive ThoughtLeader Attribute Dial™,

Much improvement has been made in the diagnosis and treatment of cancer. However, with ever increasing insight it is also clear that much more needs to be done. Many of these things are within our own hands and actions. Here is a link to an interesting article from NPR with

MDOutlook continues delivering timely post-conference insight through the Post-SABCS2014 OncoPoll™ - but with a new dimension this year. The syndicated MDOutlook post-SABCS2014 analysis focuses on breast cancer therapeutic areas where much new data was presented: new agents, adjuvant & metastatic therapy, and the emerging likelihood of biosimilars used for supportive